Affordable Access

Publisher Website

Endothelin receptor antagonists – their role in pulmonary medicine

Authors
Journal
Revue des Maladies Respiratoires
0761-8425
Publisher
Elsevier
Publication Date
Volume
28
Issue
8
Identifiers
DOI: 10.1016/j.rmr.2009.07.001
Keywords
  • Pulmonary Arterial Hypertension
  • Endothelin-Receptor Antagonists
  • Bosentan
  • Ambrisentan
  • Sitaxentan
  • Pulmonary Fibrosis
Disciplines
  • Biology
  • Medicine

Abstract

Summary Introduction Understanding of the function of endothelin-1 in the pathophysiology of endothelial disease, in particular pulmonary arterial hypertension (PAH), has paved the way for the development of endothelin-receptor antagonists (ERAs) and explains the leading role they now play in the treatment armamentarium for this disease. Background Three active ERA drugs (bosentan, sitaxentan, ambrisentan) are currently approved for the treatment of PAH in France. Several randomised clinical trials have demonstrated their efficacy and safety in PAH. Perspectives and conclusion Besides its vasoconstrictor effect, endothelin-1 (ET-1) plays a pivotal role in cell proliferation and apoptosis. ERAs are innovative drugs potentially useful in some pulmonary disorders such as idiopathic pulmonary fibrosis or systemic sclerosis, even though the preliminary results published remain insufficient or controversial. Conclusion ERAs play a major role in the management of pulmonary vascular disease. Other drugs, still under study, could prove useful in the treatment of infiltrating pneumonias.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

[Endothelin receptor antagonists - their role in p...

on Revue des maladies respiratoir... December 2009

Role of endothelin and endothelin receptor antagon...

on European Journal of Clinical I... September 2006

[Updated treatment of primary pulmonary hypertensi...

on Farmacia hospitalaria : órgan... 2004
More articles like this..